Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : News Links and Chart Links -- Ignore unavailable to you. Want to Upgrade?

To: Les H who wrote (4065)	12/15/2002 1:45:32 PM
From: Softechie	Respond to of 29600

I see AG getting the boot in 2003...FEED ME MAN!!!

To: Les H who wrote (4065)	12/16/2002 9:13:45 AM
From: Les H	Respond to of 29600

Biotech Sector Bleeds Money washingtonpost.com The great funding frenzy for biotechnology ended last year, but the end of 2002 is far more frightening to the tiny Rockville biotech EntreMed Inc. Unless it can find new investors during one of the most difficult fund-raising climates in years, it will run out of cash and out of business in 16 days. The region's biotechnology industry is in one its worst cash crunches ever. For all but a few companies, stock value has plunged, and the easy money that once poured into the sector from venture capitalists, Wall Street investment bankers and large pharmaceutical companies has dried up. While most local biotechnology firms have enough cash to last them three to 11 years, at least three -- EntreMed, Novavax Inc., and Martek Biosciences Corp. -- have a year's worth of cash or less. A year's supply is the minimum required to protect corporate assets and valuation, analysts say. Nationwide, about 25 percent of public biotechnology companies have less than a year's worth of money, according to industry newsletter BioCentury. rest of article at link above...